RxDoctor Payments DataLook up a doctor →

Emma Arquitola

Family · Gadsden, ALNPI 1700308616

Payments from drug & device makers

$12,977in general payments, 2019–2025

Across 603 payments — averaging $21.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$3K
  • AstraZeneca$996
  • Johnson & Johnson$727
  • Lilly USA, LLC$568
  • Pfizer$471
  • Seagen Inc.$458
  • plus $7K from 53 others

What the payments were for

  • Food & beverage$11,31287%
  • Education$3683%
  • Other$1,29810%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis108$3,005
AstraZeneca(2 entities)47$996
Johnson & Johnson31$727
Lilly USA, LLC34$568
Pfizer32$471
Seagen Inc.24$458
Merck20$444
Amgen27$434
E.r. Squibb & Sons, L.L.C.23$425
Incyte Corporation21$399
Sobi, Inc10$382
Eisai Inc.18$327
Bristol Myers Squibb15$301
Astellas Pharma US Inc10$287
Stemline Therapeutics Inc.9$270
Jazz Pharmaceuticals Inc.11$248
Pharmaessentia USA Corporation5$234
Octapharma USA, Inc.10$224
GSK16$216
AbbVie9$206
Takeda Pharmaceuticals U.S.A., Inc.9$203
Daiichi Sankyo Inc.10$189
Sanofi9$178
Sumitomo Pharma America, Inc.9$150
Beigene USA, Inc.8$142
Boehringer Ingelheim5$130
EMD Serono, Inc.4$90
Myovant Sciences Inc.6$81
Karyopharm Therapeutics Inc.4$81
Progenics Pharmaceuticals, Inc.4$73
Rigel Pharmaceuticals, Inc.4$66
Myriad Genetic Laboratories, Inc.4$66
Recordati_rare_diseases_inc.3$66
ADC Therapeutics America, Inc.3$60
Ipsen Biopharmaceuticals, Inc2$59
Deciphera Pharmaceuticals Inc.3$57
Pharmacosmos Therapeutics Inc.3$55
Global Blood Therapeutics, Inc.3$55
Gilead(2 entities)3$54
Puma Biotechnology, Inc.2$46
Kyowa Kirin, Inc.2$44
Beone Medicines USA, Inc.2$40
Array Biopharma Inc2$35
Servier Pharmaceuticals LLC2$33
Coherus Oncology, Inc.2$33
Regeneron Healthcare Solutions, Inc.2$28
Blueprint Medicines Corporation1$24
Epizyme, Inc.1$23
Genmab U.S., Inc.1$23
Dova Pharmaceuticals1$22
Taiho Oncology, Inc.1$19
Bayer1$19
Genentech USA, Inc.1$18
Morphosys, US Inc.1$18
Tersera Therapeutics LLC1$18
Pharmacyclics LLC, An Abbvie Company1$17
AVEO Pharmaceuticals, Inc.1$15
Sun Pharmaceutical Industries Inc.1$15
Tactile Systems Technology Inc1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,977 in reported general payments places this provider in the 95th percentile of 3,415 family providers in Alabama.

See all family providers in Alabama

Medicare billing

Part B allowed, 2024
$843,124
Medicare patients
272
Services billed
50,647

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban22$12,743
Hydroxyurea31$867
Ibandronate Sodium13$23

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$471$12,74322 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,415 family providers in Alabama.

Other family in Gadsden

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →